SCHEMBL188197

SCHEMBL188197

CCN1CCN(c2cc[c]cc2)CC1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRNA7 P36544 1/20 0.66
GAA P10253 4/20 0.61
RAD52 P43351 3/20 0.61
MAPT P10636 3/20 0.61
KDM4E B2RXH2 2/20 0.61
GFER P55789 1/20 0.61
SMN1; SMN2 Q16637 1/20 0.61
DRD2 P14416 2/20 0.47
SIGMAR1 Q99720 2/20 0.47
KMT2A Q03164 3/20 0.45
MEN1 O00255 2/20 0.42
LMNA P02545 1/20 0.42
KDM1A O60341 1/20 0.42
ADRA2A P08913 1/20 0.42
ADRA2B P18089 1/20 0.42
ADRA2C P18825 1/20 0.42
ACHE P22303 1/20 0.42
NPC1 O15118 1/20 0.40
RAB9A P51151 1/20 0.40
TDP1 Q9NUW8 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4576289 0.85 DRD2 (0.68) CHRNA7GAARAD52MAPTKDM4E
SCHEMBL5795262 0.82
SCHEMBL5539804 0.82 KDM4E (0.58) GAAKDM4EDRD2SIGMAR1LMNA
SCHEMBL5542026 0.80 KDM4E (0.65) GAAKDM4EDRD2SIGMAR1LMNA
SCHEMBL1101883 0.79 CHRNA7 (1.00) CHRNA7GAARAD52MAPTKDM4E
SCHEMBL5542882 0.79 KDM4E (0.68) GAAKDM4EDRD2SIGMAR1LMNA
SCHEMBL27921067 0.79 DRD4 (0.53) CHRNA7MAPTKDM4ESMN1; SMN2DRD2
SCHEMBL4222683 0.78 CHRNA7 (0.62) CHRNA7GAARAD52MAPTKDM4E
SCHEMBL4576516 0.78 DRD2 (0.46) CHRNA7GAAKDM4EDRD2SIGMAR1
Hydrochloric Acid SCHEMBL11555541 0.78 CHRNA7 (0.96) CHRNA7GAARAD52MAPTKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 183 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118146163-A Benzimidazole derivative and preparation method thereof 雅安职业技术学院 2024-06-07 CN claimed
US-10624897-B2 Chlorobenzene substituted azaaryl compounds TAIPEI MEDICAL UNIVERSITY (TW) 2020-04-21 US claimed
US-20190083499-A1 CHLOROBENZENE SUBSTITUTED AZAARYL COMPOUNDS TAIPEI MEDICAL UNIVERSITY (TW) 2019-03-21 US claimed
EP-2528925-B1 THIENO[3,2-d]PYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY ON PROTEIN KINASES HANMI SCIENCE CO LTD (KR) 2017-07-05 EP claimed
EP-3123864-A1 IMIDAZOPYRAZINE SYK INHIBITORS Gilead Connecticut, Inc. (US) 2017-02-01 EP claimed
EP-2373169-B1 IMIDAZOPYRAZINE SYK INHIBITORS GILEAD CONNECTICUT INC (US) 2015-05-20 EP claimed
EP-2861595-A2 SUBSTITUTED TRICYCLIC COMPOUNDS AS FGFR INHIBITORS Incyte Corporation (US) 2015-04-22 EP claimed
US-8999973-B2 Thieno[3,2-d]pyrimidine derivatives having inhibitory activity on protein kinases HANMI SCIENCE CO., LTD (KR) 2015-04-07 US claimed
US-20140336169-A1 IMIDAZOPYRAZINE SYK INHIBITORS GILEAD CONNECTICUT, INC. (US) 2014-11-13 US claimed
US-8748607-B2 Imidazopyrizine syk inhibitors GILEAD CONNECTICUT, INC. (US) 2014-06-10 US claimed
EP-2373169-A1 IMIDAZOPYRAZINE SYK INHIBITORS Gilead Connecticut, Inc. (US) 2011-10-12 EP claimed
CN-1549717-B Cysteine protease inhibitors having 2-cyano-4-aminopyrimidine structure and cathepsin K inhibitory activity and pharmaceutical use thereof NOVARTIS AG 2011-08-17 CN claimed
WO-2011093684-A2 THIENO[3,2-d]PYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY ON PROTEIN KINASES HANMI HOLDINGS CO., LTD. (KR) 2011-08-04 WO claimed
US-20100222323-A1 IMIDAZOPYRAZINE SYK INHIBITORS Kronos Bio, Inc. 2010-09-02 US claimed
WO-2010068257-A1 IMIDAZOPYRAZINE SYK INHIBITORS CGI PHARMACEUTICALS, INC. (US) 2010-06-17 WO claimed
EP-1663962-A4 COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASE ASSOCIATED WITH TRP-P8 EXPRESSION DENDREON CORP (US) 2007-08-22 EP claimed
JP-2007503392-A 2007-02-22 JP claimed
EP-1663962-A2 COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASE ASSOCIATED WITH TRP-P8 EXPRESSION DENDREON CORPORATION (US) 2006-06-07 EP claimed
US-20050054651-A1 Compositions and methods for the treatment of disease associated with Trp-p8 expression DENDREON CORPORATION (US) 2005-03-10 US claimed
WO-2005020897-A2 COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASE ASSOCIATED WITH TRP-P8 EXPRESSION DENDREON CORPORATION (US) 2005-03-10 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10624897-B2 Chlorobenzene substituted azaaryl compounds MKI67, CTCF, CDKN1A CHRNA7 4510/4885GAA 1571/4885RAD52 1236/4885
US-20190083499-A1 CHLOROBENZENE SUBSTITUTED AZAARYL COMPOUNDS MKI67, CTCF, CDKN1A CHRNA7 4510/4885GAA 1571/4885RAD52 1236/4885
US-20050054651-A1 Compositions and methods for the treatment of disease associated with Trp-p8 expression TRPC4, TRPC3, TRPC1 CHRNA7 243/4885GAA 4570/4885RAD52 4320/4885
US-20140336169-A1 IMIDAZOPYRAZINE SYK INHIBITORS SYK, BTK, ZAP70 CHRNA7 4297/4885GAA 545/4885RAD52 2717/4885
US-20100222323-A1 IMIDAZOPYRAZINE SYK INHIBITORS SYK, BTK, ZAP70 CHRNA7 4297/4885GAA 545/4885RAD52 2717/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.